General
Johnson & Johnson COVID-19 vaccine under review by European Medicines Agency over blood clots
Europe’s drug regulator says it is reviewing rare blood clots in four people in the United States who received Johnson & Johnson’s COVID-19 vaccine.
Key points:
- Johnson & Johnson said it was aware of the rare reports of blood clots, and was working with regulators to assess the data
- The US Food and Drug Administration said it was aware of the reports, but they had “not found a causal relationship with vaccination”
- It follows an investigation of blood clots reported by some people given the AstraZeneca vaccine, which has prompted some countries to change their vaccine recommendations
The European Medicines Agency’s safety committee has also been looking at how AstraZeneca’s COVID-19 vaccine is associated with very rare cases of…
Continue Reading
-
Noosa News24 hours agoNew seller disclosure laws expected to redefine property deals in Queensland
-
Business20 hours agoRetirement costs rise $1,400 a year for couples and $900 for singles
-
Business23 hours agoWhere will BHP shares be in 3 years?
-
Business22 hours agoHow to know when to buy, hold, or sell ASX shares